Ligand Specific Up-Regulation of a Renilla reniformis Luciferase-Tagged, Structurally Unstable Muscarinic M3 Chimeric G Protein-Coupled Receptor

Molecular Pharmacology

Volumn 64, Issue 6, 2003, Pages 1474-1484

  Zeng, Fu Yue ^a   McLean, Alison J ^b   Milligan, Graeme ^b   Lerner, Michael ^a   Chalmers, Derek T ^a   Behan, Dominic P ^a  

^a ARENA PHARMACEUTICALS   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ATROPINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA 2 ADRENERGIC RECEPTOR; CARBACHOL; G PROTEIN COUPLED RECEPTOR; LUCIFERASE; METHYLSCOPOLAMINE; MUSCARINIC M3 RECEPTOR;

ANIMAL CELL; ANTHOZOA; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL STRAIN COS7; CHIMERA; CONCENTRATION RESPONSE; CYCLIC AMP RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; RENILLA; REPORTER GENE; STEADY STATE; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; RATS; RECEPTOR, MUSCARINIC M3; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT FUSION PROTEINS; SULFOTRANSFERASES; UP-REGULATION;

EID: 0346996806     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.6.1474     Document Type: Article

References (40)

1. 2 receptor. J Neurochem 71:799-807.
2. 2 receptor. Mol Pharmacol 57:890-898.
3. Betuing S, Valet P, Lapalu S, Peyroulan D, Hickson G, Daviaud D, Lafontan M, and Saulnier-Blache JS (1997) Functional consequences of constitutively active alpha2A-adrenergic receptor expression in 3T3F442A preadipocytes and adipocytes. Biochem Biophys Res Commun 235:765-773.
4. Boss V, Talpade DJ, and Murphy PJ (1996) Induction of NFAT-mediated transcription by Gq-coupled receptors in lymphoid and non-lymphoid cells. J Biol Chem 271:10429-10432.
5. Boss V, Abbott KL, Wang XF, Pavlath GK, and Murphy TJ (1998) The cyclosporin A-sensitive nuclear factor of activated T cell (NFAT) proteins are expressed in vascular smooth muscle cells. Differential localization of NFAT isoforms and induction of NFAT-mediated transcription by phospholipase C-coupled cell surface receptors. J Biol Chem 273:19664-19671.
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Cohen-Armon M, Henis YI, Lkoog Y, and Sokolovsky M (1985) Interactions of quinidine and lidocaine with rat brain and heart muscarinic receptors. Biochem Biophys Res Commun 127:326-332.
8. Edwardson JM and Szekeres PG (1999) Endocytosis and recycling of muscarinic receptors. Life Sci 64:487-494.
9. Gagnon AW, Kallal L, and Benovic JL (1998) Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the β2-adrenergic receptor. J Biol Chem 273:6976-6981.
10. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, and Kobilka BK (1997a) Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 272:2587-2590.
11. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, and Kobilka BK (1997b) Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO (Eur Mol Biol Organ) J 16:6737-6747.
12. Heinflink M, Nussenveig DR, Grimberg H, Lumpumeiri M, Oron Y, and Gershergorn MC (1995) A constitutively active mutant thyrotropin-releasing hormone receptor is chronically down-regulated in pituitary cells: evidence using chlordiazepoxide arginine as a negative antagonist. Mol Endocrinol 9:1455-1460.
13. Hill SJ, Baker JG, and Rees S (2001) Reporter-gene systems for the study of G protein-coupled receptors. Curr Opin Pharmacol 1:526-532.
14. 2-adrenergic receptor down-regulation. Evidence for a pathway that does not require endocytosis. J Biol Chem 274:28900-28908.
15. Katayama S, Kito S, Miyoshi R, and Matsubayashi H (1987) Effect of calcium antagonists on muscarinic receptor subtypes in the rat brain. Brain Res 422:168-171.
16. Koenig JA and Edwardson JM (1996) Intracellular trafficking of the muscarinic acetylcholine receptor: importance of subtype and cell type. Mol Pharmacol 49:351-359.
17. 3 receptors. Mol Pharmacol 60:761-767.
18. Lee TW, Cotecchia S, and Milligan G (1997) Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1b-adrenoceptor by ligands that act as inverse agonists. Biochem J 325:733-739.
19. Lefkowitz RJ (1998) G protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J Biol Chem 273:18677-18680.
20. Leurs R, Smit MJ, Alewijnse AE and Timmerman (1998) Agonist-independent regulation of constitutively active G protein-coupled receptors. Trends Biochem Sci 23:418-422.
21. Li J, Chen C, Huang P, and Liu-Chen L (2001) Inverse agonist upregulates the constitutively active D3.49(164)Q mutant of the rat μ-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation. Mol Pharmacol 60:1064-1075.
22. 1 muscarinic acetylcholine receptor, revealed by scanning mutagenesis. J Biol Chem 274:7309-7315.
23. MacEwan DJ and Milligan G (1996a) Up-regulation of a constitutively active form of the beta2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. FEBS Lett 399:108-112.
24. MacEwan DJ and Milligan G (1996b) Inverse agonist-induced up-regulation of the human β2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. Mol Pharmacol 50:1479-1486.
25. 1-adrenoceptor. Mol Pharmacol 62:747-755.
26. 2-green fluorescent protein fusion proteins. Mol Pharmacol 56:1182-1191.
27. Milligan G and Bond RA (1997) Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18:468-474.
28. Milligan G, Stevens PA, Ramsay D, and McLean AJ (2002) Ligand rescue of constitutively active mutant receptors. Neurosignals 11:29-33.
29. Miserey-Lenkei S, Parrot C, Bardin S, Corrol P, and Clauser E (2002) Constitutive internalization of constitutively active angiotensin II AT (1A) receptor mutants is blocked by inverse agonists. J Biol Chem 277:5891-5901.
30. Nakajima T, Kurachi Y, Ito H, Takikawa R, and Sugimoto T (1989) Anti-cholinergic effects of quinidine, disopyramide, and procainamide in isolated atrial myocytes: mediation by different molecular mechanisms. Circ Res 64:297-303.
31. Niedzwiecki DM, Cubeddu LX, and Mailman RB (1989) Comparative anticholinergic properties of thioridazine, mesoridazine and sulforidazine. J Pharmacol Exp Ther 250:126-133.
32. Rasmussen SG, Jensen AD, Liapakis G, Ghanouni P, Javitch JA and Gether H (1999) Mutation of a highly conserved aspartic acid in the β2-adrenergic receptor: constitutive activation, structural instability and conformational rearrangement of transmembrane segment 6. Mol Pharmacol 56:175-184.
33. Ramsay D, Bevan N, Rees S, and Milligan G (2001) Detection of receptor ligands by monitoring selective stabilization of a Renilla luciferase-tagged, constitutively active mutant G protein-coupled receptor. Br J Pharmacol 133:315-323.
34. 2-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice. Proc Natl Acad Sci USA 94:137-141.
35. Samama P, Cotecchia S, Costa T, and Lefkowitz RJ (1993) A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
36. Smit MJ, Roovers E, Timmerman H, van de Vrede Y, Alewijnse AE, and Leurs R (1996) Two distinct pathways for histamine H2 receptor down-regulation. H2 Leu 124 → Ala receptor mutant provides evidence for a cAMP-independent action of H2 agonists. J Biol Chem 271:7574-7582.
37. 1b-adrenoceptor. Mol Pharmacol 58:438-448.
38. Wess J (1993) Molecular basis of muscarinic acetylcholine receptor function. Trends Pharmacol Sci 14:308-313.
39. Wilson MH and Limbird LE (2000) Mechanisms regulating the cell surface residence time of the α2A-adrenergic receptor. Biochemistry 39:693-700.
40. 2A-adrenerig receptor conformational stability and cell surface turnover. Mol Pharmacol 59:929-939.